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ABSTRACT 
 
Background: Plasma concentrations of natriuretic peptides decline with obesity in patients with heart 
failure. Whether this is true for other biomarkers is unknown. We investigated a wide range of 
biomarker profiles in acute heart failure across the body mass index (BMI) spectrum.  
Methods: A total of 48 biomarkers, assessing multiple pathophysiological pathways, were measured 
in 2033 patients included in PROTECT; a trial comparing the effects of rolofylline to placebo in patients 
with acute heart failure. Patients were classified into four groups according to BMI (<25, 25-30, 30-35 
and >35 kg/m2).  
Results: Of 2003 patients with known weight and height, mean age was 70±12 years and 67% were 
men. Patients with a higher BMI (>35 kg/m²) had higher blood pressures, were younger and more 
often women. Median levels of BNP were 550 pg/ml in patients with a BMI <25 kg/m2 and 319 pg/ml in 
patients with a BMI >35 kg/m2 (p<0.001). Multivariable regression revealed that BNP (β=-0.250, 
p<0.001) and RAGE (β=-0.095, p<0.007) were inversely correlated to BMI, whereas higher levels of 
uric acid (β=0.164, p<0.001), proADM (β=0.171, p<0.001), creatinine (β=0.118, p=0.003), sodium 
(β=0.101, p=0.006) and bicarbonate (β=0.094, p=0.009) were associated with higher BMI. No 
significant interaction was seen between these seven biomarkers and BMI on 180-day mortality. 
Conclusions: The plasma concentration of several biomarkers are either positively or negatively 
influenced by BMI. These findings suggest that these markers should be interpreted with caution in 
obese patients. Though concentrations differ, their prognostic value for mortality up to 180 days did 
not differ. 
Keywords: Heart failure, obesity, biomarkers, prognosis 
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INTRODUCTION 
Biomarkers play an important role in the diagnosis and management of heart failure (HF).1-4 There are 
a variety of biomarkers available for HF, reflecting several biological processes such as oxidative 
stress, myocardial stretch or injury, remodelling, inflammation, renal function or neurohumoral 
activation.5 One of the most frequently used biomarkers for the diagnosis and prognosis of HF is (NT-
pro) Brain Natriuretic Peptide (BNP), of which levels show a positive association with left ventricle 
systolic dysfunction and mortality. Serum levels of BNP are known to be lower in obese patients, 
though the underlying severity of HF does not differ. BNP is cleared by type C clearance receptors. 
Adipose tissue is known to contain more natriuretic peptide clearance receptors-C (NPR-C), which 
possibly leads to more degradation of circulating BNP.6 However, obesity is also related with lower 
circulating levels of NT-proBNP, precursor of BNP, despite the fact NT-proBNP is not degraded 
through NPR-C. A more likely explanation for the lower levels in obese patients is suggested by 
Bartels et al. They hypothesize that the expression of BNP in impaired in obese patients due to lipid 
accumulation, suggesting a link between the fat metabolism and BNP expression.7 Lower circulating 
levels have led to the suggestion different cut-off points should be used in obese patients.8 With the 
rising prevalence of obesity worldwide, HF in obese patients is a growing problem. In contrast to BNP, 
to date it is unknown how other (cardiac) biomarkers behave across the BMI spectrum. Little is known 
about a variety of clinical used markers such as Troponin, or more novel marker for HF such as 
Galectin-3 or GDF-15. The association between BMI and these markers could influence their 
interpretation in patients with a higher BMI in contrast to patients with a lower BMI. 
Therefore, we aimed to study biomarker levels in obese patients with AHF and their behavioural 
patterns across the BMI spectrum. 
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METHODS 
Study population 
The study population consisted of 2033 patients originating from the PROTECT trial (a placebo-
controlled randomized study of the selective A1 adenosine receptor antagonist Rolofylline for patients 
hospitalized with acute decompensated heart failure and volume overload to assess treatment effect 
on congestion and renal function) which had neutral results.9-11 Key inclusion criteria were dyspnea at 
rest or at minimal exertion, BNP level ≥500 pg/mL or NT-proBNP ≥2000 pg/mL and a creatinine 
clearance between 20 and 80 mL/min. Other in- and exclusion criteria are outlined in the design 
paper. A total of 48 biomarkers were determined and fully available in 1266 patients. Patients included 
in the PROTECT trial with weight and height measurements available were included in the analysis. In 
total, 2003 patients had weight and height available at day 1, and 1742 patients had known weight and 
height at day 4.  
The patients with known height and weight at admission were separated in four different 
groups based on BMI (weight (kg)/height (m)2). The groups were BMI <25 kg/m2 (group 1), 25-30 
kg/m2 (group 2), 30-35 kg/m2 (group 3) and >35 kg/m2 (group 4) according to the World Health 
Organization (WHO) groups of BMI. Initially BMI group 1 was separated in <18.5 kg/m2 and 18.5-25 
kg/m2, but there were only 18 patients with a BMI below 18.5 kg/m2. Therefore, these two groups were 
merged. 
 
Study procedures 
In total 48 biomarkers were evaluated at baseline. A number of markers (Albumin, alanine 
transaminase (ALT), aspartate transaminase (AST), bicarbonate, blood urea nitrogen (BUN), chloride, 
creatinine, glucose, hemoglobin, platelet count, potassium, red blood cell (RBC) count, sodium, total 
cholesterol, triglycerides, uric acid and white blood cell (WBC) count) were determined in ICON 
Laboratories, Farmingdale, New York. The following 26 biomarkers were assessed by Alere Inc., San 
Diego, California USA. Using enzyme-linked immunosorbent assays (ELISA) Galectin-3, 
myeloperoxidase (MPO) and neutrophil gelatinase-associated lipocalin (NGAL) were measured. By 
using competitive ELISAs on a Luminex® platform angiogenin and C-reactive protein (CRP) were 
measured. By using sandwich ELISAs on a Luminex® platform D-dimer, endothelial cell-selective 
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adhesion molecule (ESAM), growth differentiation factor 15 (GDF-15), lymphotoxin beta receptor 
(LTBR), mesothelin, neuropilin, N-terminal pro C-type natriuretic peptide (NT-proCNP), osteopontin, 
procalcitonin (PCT), pentraxin-3, periostin, polymeric immunoglobulin receptor  (PIGR), pro-
adrenomedullin (proADM), prosaposin B (PSAP-B), receptor for advanced glycation endproducts 
(RAGE), soluble ST-2 (sST-2), syndecan-1, tumor necrosis factor alpha receptor 1 (TNFR-1), Troy, 
vascular endothelial growth receptor 1 (VEGFR-1) and WAP four-disulphide core domain protein HE4 
(WAP-4C) were determined. An extra five biomarkers, Brain Natriuretic Peptide (BNP, Endothelin-1 
(ET-1), Interleukin-6 (IL-6), Kidney Injury Molecule (KIM-1) and cardiac Troponin I (cTnI) were 
assessed by single molecule counting technology by Erenna® Immunoassay System on a microtiter 
plate by Singulex Inc., Alameda, California USA. Immunoassays to PCT, proADM, Galectin-3 and ST2 
were developed by Alere. These research assays have not been standardised to the commercialised 
assays used in research or in clinical use and the extent to which each Alere assay correlates with the 
commercial assay is not fully characterized. Additional information about the assays are presented in 
Supplementary table 1. 
 
Statistical analysis 
Normally distributed data are presented as means and standard deviation, skewed data as medians 
and 25th to 75th percentiles, and categorical variables as percentages and frequencies. Intergroup 
differences between variables were tested using one-way ANOVA for normally distributed data; 
skewed data was tested using Chi-squared test or Kruskal-Wallis test depending on whether the data 
was continuous or nominal. With multivariable fractional polynomials best fit for each variable was 
estimated.  
To assess predictors of a higher BMI, multivariable linear regression models were constructed. 
A natural logarithmic transformation of BMI was used (Log BMI). Variables that might correlate with 
each other were alternated in multivariable analysis. Before entering the variables in the model 
variables were standardized by dividing them by their standard deviation. Backward as well as 
stepwise multivariable analysis was used. The final model with backward analysis consisted of 
biomarkers, demographics, medical history and prior medication. Proportional hazards survival (Cox 
PH analysis) was used to estimate the effect of BMI on mortality up to 180 days and the effect of 
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biomarker levels on mortality up to 180 days. In multivariable models to estimate the effect of BMI, 
adjustments were made for age and gender. In Cox PH analysis for biomarker levels, adjustments 
were made for age, gender and Log BMI.   
Kaplan-Meier curves were assessed to estimate the effect of BMI on mortality up to 180 days. 
Differences in survival rates between the different BMI groups were tested using the log rank test 
(Mantel-Cox test). 
Forest plots were drafted to evaluate the predictive value and hazard ratio of mortality up to 180 days 
between a BMI below 30 kg/m2 and above 30 kg/m2 put out against seven biomarkers.  
A two-sided p-value <0.05 was considered statistically significant. 
All analyses were performed using IBM SPSS Statistics version 22 and R: a Language and 
Environment for Statistical Computing, version 3.0.2. (R Foundation for Statistical Computing, Vienna, 
Austria). 
RESULTS 
Baseline characteristics 
Baseline characteristics for all 2003 patients were divided according to BMI groups. Baseline 
characteristics are shown in Table 1. Mean age for the total cohort is 70±12 years, with predominantly 
male patients (67 %). Almost half of the patients had NYHA class III (n=965). The mean LVEF in the 
total cohort was 32±13%. In patients with a BMI above 35 kg/m2, 89% (n=254) had a history of 
hypertension and 62% (n=178) had a history of diabetes mellitus. Despite these risk factors, obese 
patients were less likely to have ischemic heart disease or myocardial infarction compared to patients 
in lower BMI groups. Patients with a higher BMI were younger, less frequently male, and had higher 
systolic and diastolic blood pressures and higher heart rate. 
Biomarkers at baseline 
All biomarkers at baseline are shown in Table 2. A higher BMI is associated with a lower BNP and a 
higher Galectin-3 (p<0.001). Glucose levels are higher in patients with a BMI between 25-30 kg/m2 
and patients with a BMI between 30-35 kg/m2. The same applies to creatinine (p<0.001), plasma 
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NGAL (p<0.001), uric acid (p<0.001) and sodium (p<0.001). Widely used markers such as Troponin-I, 
CRP and IL-6 do not differ. Because BMI is determined by weight, patients with more edema could 
have had a higher BMI. The same statistics were performed with weight on day 4, in a more 
recompensated state. Data did not significantly differ in outcome (Supplementary table 2). To check 
for informed censoring, a baseline table was drafted based on all biomarkers available or not all 
biomarkers available. Data did not substantially differ (Supplementary table 3). 
Correlates for BMI 
In univariable and multivariable linear regression analyses clinical correlates for BMI are assessed and 
shown in Table 3. A lower age (β=-0.035, p<0.001), a higher diastolic blood pressure (β=0.023, 
p=0.001), a medical history of diabetes (β=0.104, p<0.001) and hypertension (β=0.085, p=0.001) are 
associated with a higher BMI. Univariable regression analyses is shown in Supplementary table 4. 
 BNP (β=-0.051, p<0.001) and RAGE (β=-0.020, p<0.007) are inversely correlated to BMI. Uric 
acid (β=0.032, p<0.001), proADM (β=0.034, p<0.001), creatinine (β=0.023, p=0.003), sodium 
(β=0.021, p=0.006) and bicarbonate (β=0.020, p=0.009) are positively correlated with BMI in a 
multivariable model. Statistics were also performed on these seven biomarkers using weight at day 4, 
which did not significantly alter our findings (Supplementary table 5).  
BMI and mortality up to 180 days 
Cox proportional hazard regression models for BMI predicting mortality up to 180 days are presented 
in Table 4. In univariable analysis, a higher BMI is associated with lower mortality rates (hazard ratio 
(HR) 0.53, p=0.019). However, in a multivariable model after adjustment for sex and age, there is no 
longer a significant association between BMI and mortality up to 180 days (HR 0.69, p=0.21).  
 Figure 1 shows the Kaplan-Meier curve for survival up to 180 days. Whereas the lowest 
survival rates are in the group with a BMI <25 kg/m2 (80%), and the best survival is seen in the group 
with a BMI 30-35 kg/m2 (86.1%); there is no significant difference between the groups (p=0.087).  
 To evaluate the predictive value of biomarkers in relation to mortality for a BMI above and 
below 30 kg/m2, Forest plots were drafted (Figure 2). Within these plots seven biomarkers associated 
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with BMI were separated into a BMI above or below 30 kg/m2. There is no significant interaction 
between BMI and any of the biomarkers.  
 
DISCUSSION 
In a wide spectrum of biomarkers, measured in a large group of patients with AHF, we show several 
biomarkers to be either positively (proADM, uric acid, creatinine, sodium and bicarbonate) or 
negatively (BNP and RAGE) correlated with BMI. The prognostic value of the biomarkers for mortality 
up to 180 days was similar in patients with lower and higher BMI.   
Cardiac biomarkers and obesity 
Previous studies have already showed that a higher BMI is associated with lower serum BNP levels, 
but despite these findings there is still no consensus about the underlying mechanism. A possible 
hypothesis is thought to be that the expression of BNP in impaired in obese patients due to lipid 
accumulation, suggesting a link between the fat metabolism and BNP expression. This could be due to 
the fact that triglyceride accumulation in the heart could lead to cellular stress and apoptosis. BNP 
induces lipolysis in adipocytes, and might reduce the release of free fatty acids and its adverse 
effects.7 Circulating levels of BNP were also strongly negatively related to patients with acute heart 
failure and a high BMI in our study. The negative correlation between BMI and BNP is not only found 
in patients with HF, but also in healthy patients.12 Our data confirms a negative relation between BMI 
and BNP which influences the clinical interpretation of circulating BNP levels. Out of the seven 
markers stated to be associated with BMI, BNP seems to be most strongly correlated with BMI. 
Christensen et al found in patients with chronic HF that only NP and adiponectin were associated with 
BMI.13 However they reviewed seven biomarkers in contrast to our 48 biomarkers, and in patients with 
chronic HF while our database consists of patients with AHF.  
  
Non-cardiac biomarkers and obesity 
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One of the biomarkers in our study which is strongly correlated to a high BMI is uric acid. Recent 
studies provided a couple of reasons why uric acid is elevated in obese patients. Uric acid is the 
product of the purine metabolism. Purines are mainly found in red meat or shellfish. One of the 
possible reasons obese patients might have higher circulating levels of uric acid is due to a higher 
intake of purines.14 Furthermore adipose tissue is known to secrete uric acid. Obesity creates more 
mRNA expression and activity of the xanthine oxidoreductase, which converts xanthine into uric acid, 
resulting in increased levels of uric acid.15,16 High uric acid levels are known to play a role in the 
development of metabolic syndrome, a clustering of abdominal obesity, insulin resistance, 
dyslipidemia and elevated blood pressures, all cardiovascular risk factors.17 Of note, we observed 
more hypertension and diabetes in our obese patients, although less ischemic heart disease and 
myocardial infarction. 
Higher levels of serum bicarbonate are also correlated with a higher BMI. Bicarbonate is more often 
raised in patients with AHF, which is linked to the use of diuretics. Depending on the choice of 
diuretics, diuretics often give electrolyte and acid disorders. Changes in potassium, sodium, uric acid 
and bicarbonate are not uncommon.18 Furthermore, studies have shown that bicarbonate is 
associated with worsening renal function, more HF events and higher mortality.18,19 A possible 
explanation for the correlation between a higher BMI and bicarbonate might be that a higher serum 
bicarbonate is associated with obesity hypoventilation syndrome. Due to chronic hypoventilation in 
obese patients bicarbonate raises in reaction to hypercapnia.20 
Another biomarker strongly associated with a high BMI in our study is proADM, a precursor for 
adrenomedullin. Adrenomedullin is a vasodilator peptide, synthesized by a variety of tissues, for 
example heart, lungs and kidney. Most important function of adrenomedullin in cardiovascular 
diseases seems to be its effects against oxidative stress.21 This biomarker has recently been 
described as strong predictor for all-cause mortality.22,23 ProADM is often raised in obese patients 
because adipose tissue contains receptor activity modifying proteins which together form the 
adrenomedullin receptor. The increased number of receptors is thought to protect against 
complications of co morbidities in obesity, like diabetes and hypertension, through vasodilatation.24 
  Furthermore several renal biomarkers were evaluated, including plasma KIM-1 and NGAL 
which are both markers of tubular damage.25 Both plasma KIM-1 and plasma NGAL are higher in 
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higher BMI groups. These higher levels of plasma KIM-1 and plasma NGAL suggests tubular damage 
in patients with a higher BMI. Despite the higher creatinine clearance found in this study, these 
findings suggest that the renal function in obese patients is worse compared to non-obese groups. 
Obese patients are more often affected by a variety of co-morbidities, such as diabetes and higher 
blood pressures. These factors could explain the decreased renal function in obese patients. 
RAGE, Receptor for advanced glycation endproducts, is expressed in the heart in cardiomyocytes, 
fibroblasts and inflammatory cells and is released following cardiomyocyte injury. Serum levels of this 
receptor could therefore reflect the degree of heart failure.26 However, the predictive value of RAGE is 
not yet fully established.27,28 While vascular cells express RAGE, this contributes to soluble forms of 
RAGE. These soluble forms of RAGE have been shown to be lower in patients with metabolic 
syndrome.  One of the possible explanations is that circulating RAGE may function as a decoy or a 
natural inhibitor to bind to the membrane RAGE receptor, and thus prevent AGEs to bind to the 
receptor and exert any biological actions. This way RAGE might play an important role in the 
development of (complications associated with) diabetes.29,30 
Obesity and mortality 
In this study we showed that a higher BMI is associated with a lower mortality risk, in accordance to 
recent studies linking (pre)obesity to significant lower mortality rates in acute HF.31-33 However after 
correction for gender and age, there is a trend towards the obesity paradox but there is no longer a 
significant correlation between BMI and survival rates. Still, there is a trend visible: a BMI between 25-
35 kg/m² is more favorable than a normal weight. To ensure our measurement using BMI on day 1 
was not overestimated by decompensation, BMI on day 4 was also used which possibly shows a more 
recompensated state. This did not give any significant alternative outcome.  
 BNP and proADM are strong predictors for (all-cause) mortality in HF patients.23,34 To evaluate 
their prognostic value on mortality up to 180 days, graphs were drafted to plot the seven biomarkers 
found to be associated with BMI separated by a BMI below and above 30 kg/m2. These hazard ratios 
were plotted along with a p-value for interaction. There is no significant interaction between any of 
these biomarkers and BMI. Thus can be concluded that levels of these biomarkers may differ in 
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patients with a higher BMI and might need to be interpreted differently, however their prognostic value 
on mortality up to 180 days does not differ.  
Study limitations 
The main limitation of our study is its retrospective design. A second limitation in our study is the 
absence of underweight patients. From 2003 patients with known BMI, only 18 people were 
underweight. In order to provide more or less even groups, patients with underweight were merged 
with normal weight patients. Furthermore, there are predominantly male patients in our cohort.  
 Another limitation concerns the non-commercial immunoassays of PCT, proADM, Galectin-3 
and ST2. These research assays have not been standardized to the commercialized assays used in 
research or in clinical use and the correlation of each Alere assay to the commercial assay is not fully 
characterized. 
CONCLUSION 
The plasma concentrations of 7 out of 48 biomarkers were either positively or negatively influenced by 
BMI. These findings suggest that these markers should be interpreted with caution in obese patients. 
Though concentrations may differ in obese patients, the prognostic value for mortality up to 180 days 
did not differ per biomarker in patients with a higher BMI. 
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Table 1; Baseline characteristics 
BMI groups (kg/m2)  <25  25-30 30-35  >35 P value 
N = 591 715 410 287  
Demographics      
Sex (% Male) 397 (67) 509 (71) 271 (66) 169 (59) 0.002 
Age (years) 
71 
±13 
72 
±11 
70 
±11 
64 
±11  <0.001 
LVEF (%) 
32 
±13 
32 
±13 
34 
±13 
33 
±14 0.27 
Systolic Blood Pressure (mmHg) 
121 
±18 
124 
±17 
127 
±16 
128 
±18 <0.001 
Diastolic Blood Pressure (mmHg) 
72 
±12 
73 
±11 
75 
±12 
76 
±13 <0.001 
Heart Rate (beats/min) 
80 
±15 
79 
±15 
80 
±16 
83 
±16 0.006 
Rolofylline administration (%) 387 (65.5) 481 (67.3) 275 (67.1) 191 (66.6) 0.92 
Medical History      
Hypertension (%) 421 (71.2) 560 (78.3) 354 (86.3) 254 (88.5) <0.001 
Diabetes Mellitus (%) 165 (27.9) 322 (45.0) 243 (59.3) 178 (62.0) <0.001 
Hyperlipidemia (%) 280 (47.4) 370 (51.7) 230 (56.1) 154 (53.7) 0.045 
Ischemic Heart Disease (%) 390 (66.0) 516 (72.2) 316 (77.1) 170 (59.2) <0.001 
Myocardial Infarction (%) 291 (49.2) 380 (53.1) 212 (51.7) 103 (35.9) <0.001 
NYHA Class     0.043 
1 5 (0.8) 9 (1.3) 4 (1.0) 1 (0.3)  
2 94 (15.9) 118 (16.5) 60 (14.6) 46 (16.0)  
3 292 (49.4) 352 (49.2) 192 (46.8) 129 (44.9)  
4 162 (27.4) 193 (27.0) 138 (33.7) 103 (35.9)  
 
Values are given as means ± standard deviation, median (25th to 75th percentiles ) or percentage and frequency 
LVEF = left ventricular ejection fraction, NYHA = New York Heart Association 
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Table 2; Biomarkers at baseline 
BMI groups (kg/m2)  <25  25-30 30-35  >35 P value 
N = 591 715 410 287  
Biomarkers      
Albumin (g/dL) 3.84 ±0.45 3.85 ±0.43 3.85 ±0.44 3.83 ±0.40 0.95 
Alt (g/dL) 
21.0 
(15-35) 
21.0 
(15-32) 
20 
(14.8-29) 
21.5 
(15-31) 0.063 
Angiogenin (ng/ml) 
1806.2 
(1212-2605) 
1866.7 
(1226-2936) 
1860.4 
(1322-2760) 
1936.8 
(1241-2886) 0.19 
Ast (U/L) 26 (20-36) 25 (20-33) 24 (18-31) 24 (18.5-32.5) 0.004 
Bicarbonate (mEq/L) 
24.0 
±3.9 
23.7 
±3.6 
23.9 
±3.9 
24.8 
±3.9 0.002 
Blood urea nitrogen (mg/dL) 
28.0 
(21-39) 
30.0 
(23-41) 
31.5 
(23-43) 
28.0 
(21-41) 0.001 
BNP (pg/ml) 
549.7 
(286-934) 
450.2 
(270-789) 
421.6 
(224-780) 
319.0 
(195-550) <0.001 
Chloride (mEq/L) 
100.4 
±5.0 
101.0 
±5.0 
101.3 
±4.9 
100.5 
±4.7 0.014 
Cholesterol total (mg/dL) 
143 
(119-171) 
140 
(115-174) 
142 
(115-174) 
137 
(114-169) 0.39 
Creatinine (mg/dL) 
1.30 
(1.08-1.60) 
1.40 
(1.20-1.80) 
1.50 
(1.20-1.90) 
1.30 
(1.10-1.80) <0.001 
CRP (mg/ml) 
13.3 
(7.0-26.5) 
13.6 
(6.6-26.9) 
14.1 
(7.6-29.8) 
15.1 
(9.3-26.8) 0.088 
D-Dimer (ng/ml) 
172.2 
(90.5-371.5) 
160.3 
(90.6-381.8) 
148.2 
(90.6-283.5) 
165.1 
(90.6-305.9) 0.20 
Endothelin 1 (pg/ml) 6.6 (4.6-9.1) 6.9 (5.1-9.2) 7.1 (5.2-9.5) 6.9 (4.9-9.3) 0.19 
ESAM (ng/ml) 
61.3 
(56.0-68.6) 
62.2 
(56.6-70.1) 
61.6 
(56.1-70.2) 
61.9 
(55.7-68.6) 0.74 
Galectin-3 (ng/ml) 
33.6 
(25.4-45.2) 
36.8 
(28.0-49.4) 
37.6 
(28.9-49.7) 
38.1 
(28.4-53.2) <0.001 
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BMI groups (kg/m2)  <25  25-30 30-35  >35 P value 
N = 591 715 410 287  
GDF-15 (nl/ml) 
4.6 
(3.1-6.3) 
4.4 
(3.1-6.3) 
4.7 
(3.1-6.3) 
4.5 
(3.0-6.3) 0.85 
Glucose (mg/dL) 
121.0 
(99-151) 
130.0 
(103-165.5) 
133.0 
(103-171) 
128.0 
(103-173) <0.001 
Hemoglobin (g/dL) 
12.8 
±2.02 
12.7 
±1.97 
12.6 
±1.97 
12.7 
±1.96 0.19 
Interleuking 6 (pg/ml) 10.8 (6.1-18.6) 11.1 (6.6-21.1) 11.6 (6.8-21) 11.7 (6.9-22.1) 0.18 
KIM-1 (pg/ml) 
247.6 
(161.3-426.9) 
301.8 
(194.7-477.4) 
320.1 
(189.9-552.1) 
333.6 
(208.2-532.8) <0.001 
LTBR (ng/ml) 
0.38 
(0.26-0.53) 
0.42 
(0.28-0.60) 
0.42 
(0.28-0.60) 
0.43 
(0.29-0.61) 0.004 
Mesothelin (ng/ml) 
86.9 
(74.5-100.1) 
87.1 
(74.8-101.6) 
86.4 
(73.3-102.1) 
85.6 
(75.1-97.4 0.76 
Myeloperoxidase (nl/ml) 
33.0 
(17.2-68.0) 
37.2 
(20.1-75.8) 
34.0 
(17.9-67.6) 
29.9 
(16.9-66.4) 0.25 
Neuropilin (ng/ml) 
13.0 
(8.3-18.1) 
12.0 
(7.8-17.3) 
12.1 
(8.2-17.2) 
12.9 
(8.7-17.5) 0.29 
NGAL (ng/ml) 
72.8 
(48.2-112.4) 
87.6 
(54.4-146) 
86.0 
(57.5-148.3) 
83.9 
(52.9-138.1) <0.001 
NTpro-CNP (ng/ml) 
0.040 
(0.029-0.059) 
0.044 
(0.030-0.060) 
0.042 
(0.031-0.059) 
0.039 
(0.026-0.061) 0.18 
Osteopontin (ng/ml) 
115.6 
(80.2-177.1) 
111.5 
(75.0-168.6) 
109.2 
(78.5-152.8) 
109.4 
(79.2-161.3) 0.21 
Pentraxin-3 (ng/ml) 
4.9 
(3.1-7.5) 
4.3 
(2.8-6.8) 
4.2 
(2.9-6.9) 
3.8 
(2.5-6.3) 0.001 
Periostin (ng/ml) 
5.9 
(3.3-9.6) 
5.3 
(3.0-8.9) 
5.4 
(3.2-8.7) 
5.5 
(3.2-8.2) 0.20 
PIGR (ng/ml) 
389.7 
(263.2-601.6) 
403.9 
(266.9-706.8) 
406.6 
(264.4-655.0) 
355.6 
(240.4-653.3) 0.31 
Potassium (mEq/L) 
4.24 
±0.60 
4.32 
±0.58 
4.29 
±0.56 
4.28 
±0.64 0.16 
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BMI groups (kg/m2)  <25  25-30 30-35  >35 P value 
N = 591 715 410 287  
proADM (nl/ml) 
2.4 
(1.4-4.4) 
2.8 
(1.6-4.9) 
2.9 
(1.6-4.8) 
3.4 
(1.9-5.5) 0.002 
Procalcitonin (nl/ml) 
0.020 
(0.010-0.048) 
0.021 
(0.010-0.050) 
0.024 
(0.014-0.046) 
0.021 
(0.011-0.055) 0.27 
Platelet count (*10^9/L) 
218.5 
(167.0-278.0) 
216.0 
(168.5-274.0) 
212.5 
(178.3-262.8) 
221.0 
(179.0-267.0) 0.75 
PSAB-B (ng/ml) 
40.3 
(30.0-55.6) 
38.5 
(28.6-53.5) 
36.9 
(27.8-51.8) 
36.5 
(25.9-49.7) 0.003 
RAGE (ng/ml) 
5.0 
(3.6-7.0) 
5.1 
(3.7-6.8) 
5.2 
(3.7-6.8) 
4.8 
(3.5-5.9) 0.042 
RBC (*10^12/L) 4.25±0.65 4.22±0.64 4.23±0.66 4.33±0.68 0.12 
Sodium (mEq/L) 138.8±4.1 139.3±4.2 139.9±4.1 139.7±3.8 <0.001 
ST-2 (ng/ml) 3.7 (1.2-8.5) 3.3 (0.96-7.9) 3.2 (0.93-7.4) 3.9 (0.93-7.1) 0.33 
Syndecan-1 (ng/ml) 8.3 (6.9-9.9) 8.3 (6.9-10.2) 8.5 (7.0-10.4) 8.4 (7.2-10.1) 0.43 
TNF-R1a (ng/ml) 2.9 (2.1-4.4) 3.3 (2.4-4.7) 3.3 (2.3-4.8) 3.3 (2.2-4.8) 0.008 
Triglycerides (mg/dL) 82.0 (59-112) 87.5 (64-122) 95.0 (68-132) 99.0 (73-134) <0.001 
Troponin I (pg/ml) 
11.0 
(5.6-23.5) 
10.7 
(5.7-24.0) 
10.7 
(5.6-21.0) 
10.1 
(5.4-22.8) 0.70 
Troy (ng/ml) 
0.08 
(0.06-0.12) 
0.10 
(0.07-0.13) 
0.09 
(0.07-0.13) 
0.09 
(0.06-0.13) <0.001 
Uric acid (mg/dL) 8.56±2.65 9.18±2.58 9.18±2.42 9.24±2.58 <0.001 
VEGFR (ng/ml) 
0.41 
(0.25-0.58) 
0.36 
(0.24-0.58) 
0.38 
(0.24-0.56) 
0.41 
(0.27-0.66) 0.068 
WAP4C (ng/ml) 
26.6 
(14.6-51.8) 
28.8 
(14.5-53.2) 
27.8 
(15.2-48.9) 
23.3 
(11.6-50.4) 0.16 
WBC (*10^9/L) 
7.2 
(5.9-8.9) 
7.6 
(6.0-9.3) 
7.6 
(6.1-9.5) 
7.6 
(6.4-9.2) 0.058 
 
Values are given as means ± standard deviation, median (25th to 75th percentiles ) or percentage and frequency 
CIRCHF/2016/003350R2   
22 
 
Alt = alanine transaminase, Ast = aspartate transaminase, BNP = brain natriuretic peptide, CRP = C-reactive protein, ESAM = endothelial cell-selective adhesion molecule, KIM-1 = kidney injury molecule 1, LTBR = 
lymphotoxin beta receptor, NGAL = neutrophil gelatinase-associated lipocalin, NTpro-CNP = N-terminal pro C-type natriuretic peptide, PIGR = polymeric immunoglobulin receptor, proADM = pro-adrenomedullin, PSAB-B = 
prosaposin B, RAGE = receptor for advanced glycation endproducts, RBC = red blood cell count, VEGFR = vascular endothelial growth receptor 1, WAP4C = WAP four-disulphide core domain protein HE4, WBC = white blood 
cell count  
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Table 3; Multivariable predictors of BMI* 
Variable β 95% CI t-value 
p-
value 
BNP (pg/ml) -0.051 -0.07--0.04 -6.95 <0.001 
History of DM 0.096 0.07-0.12 6.74 <0.001 
Age (years) -0.034 -0.05--0.02 -4.91 <0.001 
proADM (nl/ml) 0.034 0.02-0.05 4.40 <0.001 
Uric acid (mg/dL) 0.032 0.02-0.05 4.34 <0.001 
History of hypertension 0.061 0.03-0.094 3.59 <0.001 
Systolic blood pressure (mmHg) 0.025 0.01-0.04 3.28 0.001 
History of depression 0.076 0.03-0.12 3.20 0.001 
Creatinine (mg/dL) 0.023 0.01-0.04 2.98 0.003 
Sodium (mEq/L) 0.021 0.01-0.04 2.78 0.006 
RAGE (ng/ml) -0.020 -0.04-0.01 -2.69 0.007 
Bicarbonate (mEq/L) 0.020 0.01-0.03 2.63 0.009 
Heart rate (beats/min) 0.014 0.00-0.03 1.92 0.055 
 
*All univariable significant variables (p<0.1) where entered in a multivariable backward model. Only one measurement of blood pressure (systolic/diastolic) 
and renal function (creatinine, creatinine clearance, NGAL) was entered because of collinearity. 
Adjusted R² = 0.276  
 
 
Table 4; Cox PH survival regression analysis for the prediction of mortality up to 180 days 
 
180-day mortality Hazard ratio (95% CI) p-value 
Per log BMI 0.526 (0.307-0.899) 0.019 
- Adjusted for gender 0.533 (0.311-0.914) 0.022 
- Adjusted for gender and age 0.691 (0.390-1.224) 0.21 
- Adjusted for gender and BNP 0.638 (0.341-1.194) 0.16 
 
 
CIRCHF/2016/003350R2   
24 
 
Figure legends: 
Figure 1; Kaplan-Meier survival analysis by different BMI groups 
 
Figure 2; Biomarkers seperated by BMI on mortalityup to 180 days 
 
Hazard ratio for  mortality up to 180 days plotted for seven biomarkers seperated by BMI below and above 30 kg/m2. On the right p-value for interaction. No significant 
interaction is seen, concluding that a biomarker can have a predictive value on mortality up to 180 days which remains the same in a BMI above and below 30 kg/m2. 
